Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
Farmers Insurance
Express Scripts
Merck
Cipla

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 8,975,282

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,975,282
Title:Substituted pyrazolone compounds and methods of use
Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Inventor(s): Xi; Ning (Newbury Park, CA), Wu; Yanjun (Dongguan, CN), Liao; Min (Dongguan, CN), Feng; Yanming (Dongguan, CN)
Assignee: Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA)
Application Number:13/945,924
Patent Claims:see list of patent claims

Details for Patent 8,975,282

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA) 2032-07-28 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA) 2032-07-28 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA) 2032-07-28 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA) 2032-07-28 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Sunshine Lake Pharma Co., Ltd. (Dongguan, Guangdong, CN) Calitor Sciences, LLC (Newbury Park, CA) 2032-07-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Citi
Federal Trade Commission
Queensland Health
Chubb
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.